Safety and Efficacy of Preoperative Chemoradiotherapy in Patients with Locally Advanced Gastroesophageal Junction Carcinoma: Primary Results of the Multicenter Randomized PAPER Trial in Beijing, Tianjin, and Hebei Province
Y. Li,X. Li,Y. Zhang,J. Geng,Y. Cai,Z. Li,J. Ji,K. Hu,J. C. Yu,J. Jin,X. Wang,D. Zhao,B. Qu,L. Chen
DOI: https://doi.org/10.1016/j.ijrobp.2017.06.1003
2017-01-01
Abstract:To evaluate the safety and efficacy of preoperative chemoradiotherapy and D2 radical resection in patients with locally advanced gastroesophageal junction carcinoma. Gastroesophageal junction carcinomapatients withadenocarcinoma, clinical stage T3-4N0 or any TN1-3M0, Siewert type II and III were enrolled. After exclusion of peritoneal metastasis with laparoscopic exploration, patients were randomly assigned into surgery group and preoperative chemoradiotherapy plus surgery group. The preoperative chemoradiotherapy group received intensity modulated radiation therapy (IMRT) and concurrent chemotherapyS-1 combined with oxaliplatin weekly plan. Laparoscopic exploration was needed 6 weeks after the end of the preoperative chemoradiotherapy. Patients with no peritoneal metastasis underwent D2 radical resection. Postoperative patients received SOX chemotherapy for 6-8 cycles. This trial (PAPER) is a multicenter randomized controlled studyin Beijing, Tianjin and Hebei Province. Primary endpoint is 3-year DFS, the secondary endpointsare safety and effectivity. Results: Tabled 1From Sep. 2014 to Jul. 2016,40 cases of 4 centers were enrolled. There were 20 patients in surgery group and 15 cases in the preoperative chemoradiotherapy group. The median age was 61 years (range 33-73).28 were male and 7 were female. Clinical staging were as follows: 20 cT3, 15 cT4; 4 cN0, 8 cN1, 19 cN2, 13 cN3.In the preoperative chemoradiotherapy group ,All patients completed radiotherapy. Six patients cannot tolerate concurrent chemotherapy due to toxicity.There was no grade 4 toxicity.The incidence of grade 3 toxicities were 13.3%: neutropenia. The incidence of grade 2 toxicities were 80%, including: thrombocytopenia (26.7%), neutropenia (6.7%) ,esophagitis and nausea(13.3%). All patients underwent radical D2 resection. Pathological complete response occurred in 13.3% (2/15) of patients. The T and N downstaging rate were 86.7% (13/15) and 100% (11/11). respectively. Open table in a new tab The tumor regression grade (TRG) were1 case of Grade 0, 2cases of Grade 1 and 3 cases of Grade 2, respectively. Surgery-related complications consisted of anastomotic leakage in 2 (13.3%), infection in 1 (6.7%) and hemorrhage in 1 (6.7%) patients. The perioperative mortality was nil. In the surgery group, Surgery-related complications consisted of anastomotic leakage in1 (6.7%), infection in 1 (6.7%) and hemorrhage in 1 (6.7%) patients. The perioperative mortality was nil Postoperative complications had no significant differences between two groups. Preoperative Chemoradiotherapy for patients with locally advanced gastroesophageal junction adenocarcinoma showed an acceptable toxicity, promising efficacy and safety for D2 resection. Further conclusions need to be verified by the mid-term results after the completion of enrollment.